Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1134)	2/12/2008 12:49:33 PM
From: richardred	Read Replies (1) \| Respond to of 7242

BNT selling 1/2 today at 15.40.

To: richardred who wrote (1134)	3/31/2008 11:49:37 AM
From: richardred	Read Replies (1) \| Respond to of 7242

Teva to buy Bentley Pharmaceuticals' generic business for $360M Philadelphia Business Journal Generic drug maker Teva Pharmaceutical Industries Ltd. agreed Monday to buy the generic pharmaceutical operations of Bentley Pharmaceuticals Inc. for $360 million. Under the terms of the deal, shareholders of Bentley of Exeter, N.H., will receive about $15 per share in cash and undisclosed shares in CPEX Pharmaceuticals, a drug-delivery business being spun off from Bentley (NYSE:BNT). Teva said Bentley focuses on selling in Spain but also operates in other European Union counties. Shlomo Yanai, Teva's president and CEO, said the combination of Teva Spain and Bentley will give Teva a "platform to capture a leading position in the fast-growing Spanish generic pharmaceutical market." Yanai said Spain was identified as one of Teva's target markets in a strategic review the company conducted last year. Teva (NASDAQ:TEVA) initially established a presence in Spain in 2004. Since then, Teva Genericos Espanola has introduced more than 60 products in the country. Based in Jerusalem, Teva's North American headquarters are in North Wales, Pa. philadelphia.bizjournals.com